acut
exacerb
lead
caus
sever
respiratori
failur
chronic
obstruct
pulmonari
diseas
copd
patient
set
use
antibiot
recommend
recent
guidelin
european
respiratori
societi
er
french
consensu
confer
howev
bacteria
isol
respiratori
tract
approxim
patient
sever
acut
exacerb
copd
aecopd
whether
find
repres
colon
infect
controversi
contrast
high
preval
respiratori
virus
report
sever
aecopd
requir
ventil
context
rapid
specif
test
identifi
lower
respiratori
bacteri
infect
would
major
advanc
limit
inappropri
use
antibiot
consid
main
caus
spread
antibioticresist
bacteria
serum
procalcitonin
level
consid
one
best
biomark
predict
bacteri
infect
level
circul
procalcitonin
increas
sever
bacteri
infect
remain
fairli
low
viral
infect
non
specif
inflammatori
diseas
addit
procalcitoninbas
therapeut
strategi
shown
substanti
safe
reduc
antibiot
use
patient
sever
lower
respiratori
tract
infect
acut
exacerb
copd
howev
studi
specif
assess
marker
critic
ill
patient
scarc
aim
current
studi
assess
procalcitonin
level
relationship
virus
bacteria
respiratori
sampl
copd
patient
admit
icu
aecopd
copd
patient
suspect
lower
respiratori
tract
infect
admit
medic
intens
care
unit
univers
hospit
caen
septemb
septemb
assess
elig
aecopd
includ
analysi
patient
presenc
infiltr
chest
radiograph
taken
admiss
suspect
pneumonia
exhibit
evid
caus
respiratori
failur
includ
studi
defin
copd
accord
global
initi
chronic
obstruct
lung
diseas
guidelin
gold
ratio
forc
expiratori
volum
secondfunct
vital
capac
less
sever
categor
mild
predict
moder
sever
sever
aecopd
defin
sustain
worsen
patient
condit
stabl
state
beyond
normal
daytoday
variat
acut
onset
necessit
chang
regular
medic
patient
underli
copd
aecopd
consid
bacteriolog
confirm
presenc
posit
gram
stain
respiratori
sampl
pathogen
concentr
greater
tracheobronchi
aspir
blood
cultur
reveal
bacteri
pathogen
absenc
extrapulmonari
focu
cultur
indirect
immunofluoresc
assay
ifa
polymeras
chain
reaction
pcr
assay
posit
virus
consid
evid
viral
pathogen
protocol
prospect
cohort
studi
submit
local
ethic
committe
ethic
board
decid
approv
necessari
given
observ
natur
studi
thu
accord
french
legisl
time
studi
inform
consent
obtain
patient
upon
admiss
icu
baselin
assess
includ
sever
copd
accord
gold
criteria
home
oxygen
home
noninvas
ventil
treatment
chronic
steroid
therapi
comorbid
cigarett
smoke
chronic
alcohol
abus
obes
diabet
mellitu
chronic
cardiovascular
diseas
use
antibiot
therapi
oral
steroid
exacerb
copd
previou
period
use
antibiot
within
hour
icu
admiss
physic
examin
chest
radiographi
routin
blood
test
includ
creactiv
protein
crp
admiss
hour
later
addit
score
diseas
sever
first
day
icu
assess
simplifi
acut
physiolog
score
type
ii
sap
ii
acut
physiolog
chronic
health
evalu
apach
ii
score
logist
organ
dysfunct
lod
score
patient
treat
accord
recommend
french
consensu
confer
blood
sampl
centrifug
decant
aliquot
frozen
analyz
end
studi
period
pct
measur
use
sensit
immunoassay
kryptor
pct
brahm
hennigsdorf
germani
function
assay
sensit
fourfold
mean
normal
level
circul
level
procalcitonin
sequenti
assess
icu
admiss
six
hour
twenti
four
hour
patient
classifi
three
group
base
probabl
bacteri
infect
accord
highest
procalcitonin
level
measur
pctmax
previous
report
pctmax
indic
absenc
infect
group
pctmax
indic
possibl
infect
group
pctmax
indic
presenc
infect
upon
enrol
spontan
expector
sputum
sampl
tracheal
aspir
obtain
gram
stain
cultur
bacteri
isol
identif
perform
use
standard
techniqu
sputum
tracheal
aspir
bacteriolog
process
less
observ
field
contain
squamou
epitheli
cell
neutrophil
observ
serolog
diagnost
antibodi
legionella
pneumophila
also
perform
indirect
immunofluoresc
associ
detect
legionella
pneumophila
serogroup
antigen
urin
sampl
addit
nasal
swab
tracheobronchi
aspir
perform
patient
test
virus
detail
viral
detect
method
includ
cultur
indirect
immunofluoresc
assay
ifa
molecular
method
pcr
rtpcr
publish
elsewher
test
follow
virus
parainfluenza
viru
piv
influenza
viru
b
c
respiratori
syncyti
viru
rsv
metapneumoviru
hmpv
rhinoviru
rv
coronaviru
adenoviru
adv
chlamydia
pneumonia
mycoplasma
pneumonia
also
detect
pcr
assay
quantit
qualit
data
express
mean
sd
median
interquartil
rang
percentag
ci
respect
categor
variabl
compar
use
chisquar
fischer
exact
test
appropri
quantit
variabl
compar
use
student
ttest
mannwhitney
non
parametr
test
appropri
confid
interv
percentag
base
normal
approxim
level
signific
set
test
twosid
use
epiinfo
version
dfr
epiinfo
cdc
atlanta
ga
data
collect
epiinfo
sa
version
sa
institut
inc
cari
nc
data
analysi
period
studi
copd
patient
suspect
lower
respiratori
tract
infect
admit
icu
aecopd
figur
baselin
characterist
aecopd
patient
shown
tabl
twenti
nine
patient
sever
sever
copd
twenti
seven
receiv
home
oxygen
home
noninvas
ventil
use
antibiot
therapi
oral
steroid
exacerb
copd
previou
period
report
patient
respect
nine
patient
receiv
antibiot
within
hour
icu
admiss
follow
treatment
given
admiss
non
invas
ventil
niv
patient
mechan
ventil
patient
niv
failur
antibiot
patient
system
steroid
patient
inhal
steroid
patient
circul
level
procalcitonin
shown
figur
median
interquartil
rang
procalcitonin
level
admiss
procalcitonin
level
differ
patient
receiv
antibiot
month
hour
prior
icu
admiss
compar
antibioticna
patient
vs
p
vs
p
respect
associ
level
presenc
absenc
sputum
vs
p
cough
vs
p
wheez
vs
p
fever
ie
temperatur
vs
p
pctmax
patient
patient
patient
associ
pctmax
level
sever
copd
p
patient
pctmax
critic
ill
sap
ii
vs
among
patient
pctmax
p
lod
vs
among
patient
pctmax
p
median
crp
level
admiss
mgl
mgl
significantli
higher
among
pctmax
vs
p
vs
p
sampl
taken
admiss
form
sputum
tracheobronchi
aspir
nasal
swab
bacteria
viral
studi
patient
respect
fail
technic
problem
patient
respect
addit
hemocultur
legionella
diagnost
test
perform
patient
respect
accord
definit
patient
aecopd
microbiolog
confirm
five
speci
bacteria
pseudomona
aeruginosa
haemophilu
influenza
speci
virus
rhinoviru
human
metapneumoviru
parainfluenza
parinfluenza
detect
coinfect
detect
case
rhinoviru
pseudomona
aeruginosa
rhinoviru
haemophilu
influenza
level
differ
patient
without
aecopd
bacteriolog
confirm
vs
p
four
patient
pseudomona
aeruginosa
pctmax
three
known
chronic
colon
germ
pctmax
positiveviru
respiratori
sampl
influenc
pct
level
admiss
vs
p
icu
stay
noninvas
ventil
mechan
ventil
perform
patient
mean
length
noninvas
ventil
mechan
ventil
icu
stay
without
ventil
day
respect
correl
find
procalcitonin
level
data
shown
mean
length
icu
stay
day
one
patient
develop
ventilatorassoci
pneumonia
die
copdrel
respiratori
failur
seven
day
icu
discharg
patient
pct
level
increas
first
hour
patient
develop
septic
shock
thirti
five
patient
discharg
hospit
twelv
patient
subsequ
hospitalis
aecopd
within
month
pctmax
predict
recurr
data
shown
four
patient
die
three
copdrel
respiratori
failur
one
pneumothorax
complic
cardiac
arrest
sever
copd
pctmax
univari
analysi
pct
level
associ
mortal
vs
death
among
pct
p
present
studi
report
procalcitonin
level
critic
ill
copd
patient
admit
aecopd
sever
condit
accord
global
initi
chronic
obstruct
lung
diseas
criteria
agreement
previou
report
pct
level
could
indic
absenc
infect
approxim
patient
subgroup
bacteria
detect
systemat
screen
except
pseudomona
aeruginosa
three
patient
known
chronic
colon
pathogen
preliminari
result
may
import
implic
investig
procalcitoninbas
antibiot
strategi
sever
aecopd
find
differ
previou
studi
assess
microbiolog
pattern
aecopd
report
higher
preval
bacteria
vari
differ
inclus
criteria
diagnost
test
absenc
respiratori
sampl
bacteria
detect
quarter
patient
may
explain
differ
rate
virusposit
respiratori
sampl
consist
preval
respiratori
viral
infect
observ
recent
prospect
studi
use
molecular
method
focus
copd
patient
found
pct
level
copd
patient
admit
icu
sever
aecopd
consist
previou
studi
set
howev
two
larg
prospect
cohort
focus
hospit
aecopd
less
patient
admit
icu
accord
stolz
et
al
pct
level
differ
patient
pretreat
antibiot
antibioticna
patient
associ
found
pct
level
clinic
symptom
aecopd
bacteriolog
confirm
addit
proport
patient
particular
level
pct
accord
previou
report
suggest
larg
fraction
patient
low
pct
level
pctmax
low
likelihood
bacteri
infect
subgroup
one
pathogen
pseudomona
aeruginosa
detect
three
patient
known
chronic
colon
germ
whether
find
repres
colon
infect
remain
controversi
could
explain
pct
measur
fail
identifi
patient
aecopd
bacteriolog
document
studi
one
case
rhinoviru
isol
associ
pseudomona
aeruginosa
consid
caus
exacerb
moreov
report
lower
respiratori
tract
viral
infect
significantli
influenc
pct
level
set
addit
despit
small
sampl
size
abl
demonstr
signific
impact
pct
pct
cohort
predict
icu
mortal
previous
report
studi
focus
septic
shock
ventilatorassoci
pneumonia
studi
limit
monocentr
design
studi
rel
small
sampl
size
well
fact
sputum
could
taken
patient
bacteria
detect
may
limit
interpret
relev
data
howev
pct
assess
perform
patient
use
technolog
recogn
sensit
find
consist
previou
studi
reason
believ
studi
add
use
inform
pct
level
sever
aecopd
requir
icu
stay
likelihood
bacteri
infect
result
report
may
import
implic
design
random
control
trial
test
procalcitoninbas
antibiot
strategi
sever
aecopd
demonstr
antibiot
margin
efficaci
treatment
aecopd
except
among
patient
evid
bacteri
infect
sever
exacerb
less
sever
aecopd
may
attribut
bacteria
suggest
potenti
excess
antibiot
use
set
therefor
serum
procalcitonin
level
may
consid
use
tool
predict
bacteri
infect
may
prove
use
select
patient
lower
probabl
bacteri
infect
limit
inappropri
use
antibiot
specif
icu
set
antibiot
use
emerg
antimicrobi
resist
highli
preval
context
specul
antibiot
use
subgroup
sever
aecopd
lower
pct
could
reduc
previous
report
studi
assess
procalcitoninbas
antibiot
strategi
nonsever
lower
respiratori
tract
infect
result
support
patient
admit
icu
aecopd
low
likelihood
bacteri
infect
correl
pct
less
suggest
possibl
inappropri
use
antibiot
howev
studi
necessari
assess
shortterm
effect
procalcitoninbas
therapeut
strategi
critic
ill
copd
patient
icu
secondli
address
role
antimicrobi
agent
copd
patient
longterm
particularli
patient
low
pct
level
bacteriaposit
sputum
aecopd
acut
exacerb
chronic
obstruct
pulmonari
diseas
apach
ii
acut
physiolog
chronic
health
evalu
type
ii
micu
medic
intens
care
unit
ifa
indirect
immunofluoresc
assay
lod
logist
organ
dysfunct
system
pcr
polymeras
chain
reaction
pct
procalcitonin
sap
ii
simplifi
acut
physiolog
score
ii
author
declar
compet
interest
cd
mr
initi
studi
design
experiment
protocol
av
ff
perform
virolog
assess
sf
perform
pct
measur
cd
jjp
perform
statist
analysi
involv
interpret
result
cd
wrote
manuscript
jjp
mr
ddc
help
draft
manuscript
ddc
mr
nt
pc
contribut
concept
design
studi
revis
manuscript
author
read
approv
final
manuscript
prepubl
histori
paper
access
